Current Edition

Dupixent

Sanofi and Regeneron’s Dupixent aces another test, this time in the debilitating itch condition prurigo nodularis

Sanofi and Regeneron have big ambitions for immunology superstar Dupixent—envisioning the potential for $11 billion in annual sales. In acing a test in people with …

Continue Reading →